[go: up one dir, main page]

NO20091761L - Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav - Google Patents

Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav

Info

Publication number
NO20091761L
NO20091761L NO20091761A NO20091761A NO20091761L NO 20091761 L NO20091761 L NO 20091761L NO 20091761 A NO20091761 A NO 20091761A NO 20091761 A NO20091761 A NO 20091761A NO 20091761 L NO20091761 L NO 20091761L
Authority
NO
Norway
Prior art keywords
vaccine
preparation
virus
virus vaccine
vaccine formulations
Prior art date
Application number
NO20091761A
Other languages
English (en)
Inventor
Lutz Gissmann
Martin Mueller
Original Assignee
Univ Loyola Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20091761L publication Critical patent/NO20091761L/no
Application filed by Univ Loyola Chicago filed Critical Univ Loyola Chicago

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives vaksineformuleringer omfattende virale kapsomerer, og fremgangsmåter for deres fremstilling. Terapeutiske og profylaktiske fremgangsmåter for anvendelse av vaksineformuleringene beskrives også.
NO20091761A 1997-10-06 2009-05-04 Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav NO20091761L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/944,368 US6228368B1 (en) 1997-10-06 1997-10-06 Papilloma virus capsomere formulations and method of use
PCT/US1998/020965 WO1999018220A1 (en) 1997-10-06 1998-10-06 Papilloma virus capsomere vaccine formulations and methods of use

Publications (1)

Publication Number Publication Date
NO20091761L true NO20091761L (no) 2000-06-02

Family

ID=25481268

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001768A NO328128B1 (no) 1997-10-06 2000-04-06 Antigenisk formulering som omfatter et humant papillomaviruskapsomer for anvendelse som en vaksine, samt anvendelse derav for fremstilling av en farmasoytisk sammensetning for behandling og forebygging av HPV infeksjon og tilstander beslektet dermed.
NO20091761A NO20091761L (no) 1997-10-06 2009-05-04 Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20001768A NO328128B1 (no) 1997-10-06 2000-04-06 Antigenisk formulering som omfatter et humant papillomaviruskapsomer for anvendelse som en vaksine, samt anvendelse derav for fremstilling av en farmasoytisk sammensetning for behandling og forebygging av HPV infeksjon og tilstander beslektet dermed.

Country Status (21)

Country Link
US (4) US6228368B1 (no)
EP (2) EP1690941B1 (no)
JP (3) JP4520034B2 (no)
KR (1) KR20010030969A (no)
AT (2) ATE449852T1 (no)
AU (1) AU9684698A (no)
BR (1) BR9814606A (no)
CA (1) CA2305382A1 (no)
CY (1) CY1105963T1 (no)
CZ (1) CZ302351B6 (no)
DE (2) DE69841342D1 (no)
DK (1) DK1021547T3 (no)
ES (2) ES2280104T3 (no)
HU (1) HU225893B1 (no)
IL (3) IL135528A0 (no)
NO (2) NO328128B1 (no)
NZ (1) NZ503830A (no)
PL (1) PL195332B1 (no)
PT (1) PT1021547E (no)
TR (1) TR200001842T2 (no)
WO (1) WO1999018220A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
WO1998054325A1 (en) * 1997-05-29 1998-12-03 The Government Of The United States Of America,Re Presented By The Secretary, Department Of Health And Human Services Human frp and fragments thereof including methods for using them
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US20020039584A1 (en) * 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) * 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19905883C2 (de) 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
FI107932B (fi) * 1999-02-16 2001-10-31 Mikael Paronen Polymeerikalvo ja menetelmä sen valmistamiseksi
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
ES2233437T3 (es) * 1999-08-25 2005-06-16 MERCK & CO., INC. Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas.
ATE426803T1 (de) * 1999-12-09 2009-04-15 Medimmune Inc In-vitro-methode zur zerlegung und zum wiederzusammenfugen von papillomavirusartigen partikeln
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
DE10059630A1 (de) * 2000-12-01 2002-06-06 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von durch humanen Papillomavirus-Typ 18-hervorgerufenem Tumor
US7247433B2 (en) 2001-08-13 2007-07-24 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
AP2004003020A0 (en) * 2001-08-31 2004-06-30 Univ Cape Town Pharmaceutical compositions, and a method of preparing and isolating said pharmaceutical compositions, and use of said pharmaceutical compositions for prophylactic treatment of lesions and carcinomas
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
AU2003232951B2 (en) † 2002-05-17 2009-07-23 University Of Cape Town Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles.
BR0312474A (pt) 2002-07-05 2005-04-26 Denis Leclerc Partìcula viral adjuvante
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
SE0202896D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method for estimating the risk of carcinoma development
SE0202897D0 (sv) * 2002-10-01 2002-10-01 Quantovir Ab Method and kit for quantitative and qualitative determination of human papillomavirus
US7763259B2 (en) * 2003-01-10 2010-07-27 The Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US7172773B2 (en) * 2004-04-26 2007-02-06 Renew Life Inc. Food supplement formulation
EP1790332B1 (en) * 2004-09-10 2010-07-21 Asahi Glass Company, Limited Human papilloma virus vaccine for oral administration
EP1819835B1 (en) * 2004-12-08 2010-08-04 Gen-Probe Incorporated Detection of nucleic acids from multiple types of human papillomaviruses
US7314630B2 (en) * 2005-01-07 2008-01-01 Yao-Xiong Hu Compounds and methods of early diagnosis of cervical cancer and genital condyloma with HPV, CHSP60 tumor suppressor H-Ras, K-Ras and PTEN derived peptides modified
DK2154147T3 (en) * 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
EP2147926B1 (en) 2007-04-29 2016-08-24 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
DK2154149T3 (da) * 2007-05-29 2019-10-14 Univ Xiamen En trunkeret l1-protein af human papillomavirus 6
US8507811B2 (en) * 2009-02-02 2013-08-13 Apple Inc. Touch sensor panels with reduced static capacitance
EP2377879A1 (en) * 2010-04-14 2011-10-19 Deutsches Krebsforschungszentrum N-terminal HPV E7 fusion proteins
US10413603B2 (en) 2014-06-19 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for improved human papilloma virus constructs
WO2016026919A1 (en) * 2014-08-20 2016-02-25 Ruprecht-Karls-Universität Heidelberg Vaccines and manufacturing methods for treatment and prevention of disease
WO2021013067A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
US11510750B2 (en) 2020-05-08 2022-11-29 Globus Medical, Inc. Leveraging two-dimensional digital imaging and communication in medicine imagery in three-dimensional extended reality applications
US11382700B2 (en) 2020-05-08 2022-07-12 Globus Medical Inc. Extended reality headset tool tracking and control

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471147A3 (en) 1991-07-19 2007-03-21 The University Of Queensland Method of making a recombinant molecule for the expression of HPV-16 L1 protein
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
WO1994000152A1 (en) 1992-06-25 1994-01-06 Georgetown University Papillomavirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
DE05075369T1 (de) * 1993-03-09 2006-11-16 The University Of Rochester Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
DE4435907C2 (de) 1994-10-07 1997-07-24 Lutz Prof Dr Gissmann Papillomavirusähnliche Partikel und deren Anwendung
JP3413020B2 (ja) * 1996-07-17 2003-06-03 株式会社東芝 半導体装置の製造方法
DE19712541C1 (de) 1997-03-25 1998-11-05 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
AU755679B2 (en) * 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
WO1999010557A1 (fr) 1997-08-26 1999-03-04 Nsk Ltd. Procede de production d'un palier a roulement
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use

Also Published As

Publication number Publication date
NZ503830A (en) 2002-09-27
PL339735A1 (en) 2001-01-02
TR200001842T2 (tr) 2000-12-21
BR9814606A (pt) 2002-01-02
EP1021547B1 (en) 2006-12-27
IL135528A (en) 2008-06-05
CA2305382A1 (en) 1999-04-15
IL190554A0 (en) 2008-11-03
US20060198853A1 (en) 2006-09-07
US20050031636A1 (en) 2005-02-10
ES2280104T3 (es) 2007-09-01
DK1021547T3 (da) 2007-04-23
CY1105963T1 (el) 2011-04-06
US6228368B1 (en) 2001-05-08
JP2013147507A (ja) 2013-08-01
KR20010030969A (ko) 2001-04-16
PL195332B1 (pl) 2007-09-28
DE69841342D1 (de) 2010-01-07
EP1690941A1 (en) 2006-08-16
JP2001519161A (ja) 2001-10-23
NO20001768D0 (no) 2000-04-06
JP4520034B2 (ja) 2010-08-04
DE69836753T2 (de) 2007-10-25
HU225893B1 (en) 2007-12-28
EP1690941B1 (en) 2009-11-25
HUP0004360A2 (en) 2001-03-28
JP5296665B2 (ja) 2013-09-25
CZ20001244A3 (en) 2001-05-16
HUP0004360A3 (en) 2003-03-28
ATE349536T1 (de) 2007-01-15
DE69836753D1 (de) 2007-02-08
ES2337492T3 (es) 2010-04-26
ATE449852T1 (de) 2009-12-15
CZ302351B6 (cs) 2011-03-30
US7754430B2 (en) 2010-07-13
PT1021547E (pt) 2007-02-28
US7371391B2 (en) 2008-05-13
US20090028894A1 (en) 2009-01-29
NO20001768L (no) 2000-06-02
JP2010095530A (ja) 2010-04-30
IL135528A0 (en) 2001-05-20
WO1999018220A1 (en) 1999-04-15
NO328128B1 (no) 2009-12-14
AU9684698A (en) 1999-04-27
EP1021547A1 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
EP0757717A4 (en) PAPILLOMAVIRUS VACCINE
WO2001034801A3 (en) Recombinant gelatin in vaccines
DK0869126T3 (da) Dithiolanderivater, deres fremstilling og deres terapeutiske virkning
EE200300331A (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarüootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
NO20011162L (no) Fremgangsmåter og preparater for modulering av interaksjonen mellom APJ-reseptoren og HIV-viruset
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
DK1047446T3 (da) Vaccinesammensætning til Herpes Simplex virus og fremgangsmåder til anvendelser deraf
EP1173204A4 (en) HUMANE CD80 MUTANTE AND COMPOSITIONS AND METHODS FOR THE PRODUCTION AND USE THEREOF
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
AU4088697A (en) Postinfection human immunodeficiency virus (hiv) vaccination therapy
EP0366238A3 (en) Influenza vaccinal polypeptides
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
NO984624D0 (no) Nye furan-diarylmetyliden-derivater, fremgangsmÕte for deres fremstilling og terapeutiske anvendelser derav
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
ES8800358A1 (es) Un procedimiento para preparar un polipeptido hibrido.
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse
AU2736600A (en) Control of virus infection using replication associated proteins, compositions and methods of use
NO20003606L (no) Triazepinoner, fremgangsmÕte for deres fremstilling, samt deres terapeutiske anvendelse
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.
GB9503395D0 (en) Viral,preparations,immunogens,and vaccines

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application